脂質異常症におけるロスバスタチン低用量（2.5 mg）からエゼチミブ追加投与あるいはロスバスタチン倍量（5 mg）投与への切り替えの検討

The percentage of change from baseline in low−density lipoprotein cholesterol（LDL−C）after the addition of ezetimibe 10 mg to rosuvastatin 2.5 mg was compared with uptitration torosuvastatin 5 mg. The subjects enrolled in the study were thirty−four out−patients（fourteenmales and twenty females, mean age：64.3 years）with hyperlipidemia who had never beentreated, but after being given rosuvastatin 2.5 mg for six months as initial therapy, had failedto reach the goals of LDL−C levels set by the Japan Atherosclerosis Society Guidelines forPrevention of Atherosclerotic Cardiovascular Diseases 2007 edition（LDL−C levels droppedfrom196.6±27.2 to 129.5±28.0 mg／dL（−34％））. The subjects were randomly assigned intoone of the two groups：rosuvastatin 2.5 mg plus ezetimibe 10 mg or uptitration to rosuvastatin5 mg. After 6 months of treatment, rosuvastatin 2.5 mg plus ezetimibe 10 mg significantlyreduced LDL−C by −31.2％ compared with rosuvastatin 5 mg by −17.5％（p＜0.01）. Also,LDL−C reductions from the baselines showed a significant difference（54.7％ versus 46.7％, p＜0.05）. No specific adverse events were found in either group. In conclusion, these resultsshowed that adding ezetimibe to rosuvastatin 2.5 mg was significantly more effective thanuptitrating to rosuvastatin 2.5 mg at lowering LDL−C.（Jpn Pharmacol Ther 2010；38：305−11）KEY WORDS Rosuvastatin, Increase of statin, Ezetimibe, Combination of ezetimibe